COVID-19 impairs glucose homeostasis and metabolism in non- and diabetes mellitus (DM) and metabolic syndrome (MS) patients due to the cytokine storm, inflammation, angiotensin II-converting enzyme (ACE2) down-regulation and the direct injury to the pancreatic β-cells [2]. This evidence concerns the gene ACE2 and COVID-19.